Pelthos Therapeutics Approves 2026 Equity Incentive Plan

What Happened
Pelthos Therapeutics Inc. (PTHS) announced via Form 8-K filed October 1, 2026 that its stockholders approved the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan at the company’s Annual Meeting. The 2026 Plan, previously approved by the Board subject to stockholder approval, became effective immediately upon that approval. The Proxy Statement describing the material terms was filed on August 18, 2026, and the full 2026 Plan is attached as Exhibit 10.1 to the 8-K.

Key Details

• Stockholders approved the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan at the Annual Meeting; it replaces the 2023 Equity Incentive Plan (as amended and restated).
• The 2026 Plan became effective immediately upon stockholder approval.
• A summary of material terms appears in the Definitive Proxy Statement filed August 18, 2026; the complete 2026 Plan is filed as Exhibit 10.1 to the Form 8-K.
• The Form 8-K was signed by John M. Gay, Chief Financial Officer, Treasurer and Secretary, on October 1, 2026.

Why It Matters
Approval of a new equity incentive plan sets the framework for future stock-based awards to employees, directors and consultants — a primary tool for compensation and retention in biopharma. For investors, the change is important because it replaces the prior 2023 plan and governs how the company may grant equity going forward; details on award types, share reserves and potential dilution are described in the proxy/plan documents filed with the 8-K. Review the attached Exhibit 10.1 and the August 18, 2026 Proxy Statement for specifics on award limits and terms.